Skip to main content
Show — Main navigation Hide — Main navigation
  • Home
  • About
    • The Chair
    • Inquiry Team
    • Expert Groups
    • Inquiry Intermediaries
    • Core Participants
    • Legal Representatives
    • Financial Reports
  • Approach
    • Terms of reference
    • List of Issues
    • Statements of approach
    • Inquiry Principles
  • News
    • News
    • Newsletter Archive
  • Reports
    • Compensation Framework Study
    • First Interim Report
    • Second Interim Report
    • The Inquiry Report
  • Publication Day
  • Evidence
    • Evidence
    • Hearings Archive
  • Compensation
  • Support
    • Confidential Psychological Support
    • Interim Payments
    • Support Groups
    • Get in touch
    • Infected Blood Support Schemes
    • Treatment and aftercare
    • Medical Evidence
    • Expenses Guidance
Accessibility Tool
  • Zoom in
  • Zoom out
  • Reset
  • Contrast
  • Accessibility tool
Get in touch

Quick Exit

In a letter from Armour Dr P Harris stated that it should not be overlooked that there may be material in centres or in patients' homes that was not derived from donors tested for anti HTLV-III.

  • Read more about In a letter from Armour Dr P Harris stated that it should not be overlooked that there may be material in centres or in patients' homes that was not derived from donors tested for anti HTLV-III.

At the meeting between Rorer Healthcare and the DHSS they discussed two cases of seroconversion and discussed if they could hold it from breaking into the public domain for a little longer. They said Dr Hill did not intend to disclose the cases to the haemophilia centre directors unless it was absolutely essential but would have to inform the parents of the children.

  • Read more about At the meeting between Rorer Healthcare and the DHSS they discussed two cases of seroconversion and discussed if they could hold it from breaking into the public domain for a little longer. They said Dr Hill did not intend to disclose the cases to the haemophilia centre directors unless it was absolutely essential but would have to inform the parents of the children.

At a meeting between the representatives of Rorer Healthcare and the DHSS, the DHSS accepted that the data on viral inactivation presented did look in favour of the heat treatment process. However due to two cases of seroconversion despite heat treatment the DHSS would look carefully to decide if it were necessary to make the company voluntarily withdraw the product.

  • Read more about At a meeting between the representatives of Rorer Healthcare and the DHSS, the DHSS accepted that the data on viral inactivation presented did look in favour of the heat treatment process. However due to two cases of seroconversion despite heat treatment the DHSS would look carefully to decide if it were necessary to make the company voluntarily withdraw the product.

In an interoffice memo from Amour, Dr Christie stated that they had a meeting with the DHSS and that there was no evidence that the DHSS regarded Armour products and their current heat treatment method as unsatisfactory and no indication that the DHSS wished for them to withdraw batches of product from unscreened donor pools.

  • Read more about In an interoffice memo from Amour, Dr Christie stated that they had a meeting with the DHSS and that there was no evidence that the DHSS regarded Armour products and their current heat treatment method as unsatisfactory and no indication that the DHSS wished for them to withdraw batches of product from unscreened donor pools.

In a meeting with Armour officials, it was decided that unscreened product would not be distributed as long as or unless there were no other product to distribute.

  • Read more about In a meeting with Armour officials, it was decided that unscreened product would not be distributed as long as or unless there were no other product to distribute.

Dr Jones wrote to Armour to say that, in particular, their product should not be given to "previously untreated seronegative patients" and that he was "particularly averse to its prescription for children."

  • Read more about Dr Jones wrote to Armour to say that, in particular, their product should not be given to "previously untreated seronegative patients" and that he was "particularly averse to its prescription for children."

A copy of the memo from Dr Peter Harris stated that infected batches of Factorate would be withdrawn due to the announcement that four patients had tested positive for HIV after receiving a batch of Factorate.

  • Read more about A copy of the memo from Dr Peter Harris stated that infected batches of Factorate would be withdrawn due to the announcement that four patients had tested positive for HIV after receiving a batch of Factorate.

Robert Christie produced a document documenting the fallout from Dr Jones' revelations and stated that his view was premature and speculative.

  • Read more about Robert Christie produced a document documenting the fallout from Dr Jones' revelations and stated that his view was premature and speculative.

Dr Donald Acheson criticised Peter Jones for going on record regarding suspected infections after using Armour produced Factor 8.

  • Read more about Dr Donald Acheson criticised Peter Jones for going on record regarding suspected infections after using Armour produced Factor 8.

Dr Peter Jones told a conference in Newcastle of suspected seroconversions of HIV after using the Armour produced Factor 8 in the Netherlands and the US.

  • Read more about Dr Peter Jones told a conference in Newcastle of suspected seroconversions of HIV after using the Armour produced Factor 8 in the Netherlands and the US.

Pagination

  • First page « First
  • Previous page ‹ Previous
  • …
  • Page 227
  • Page 228
  • Page 229
  • Page 230
  • Current page 231
  • Page 232
  • Page 233
  • Page 234
  • Page 235
  • …
  • Next page Next ›
  • Last page Last »
Subscribe to

Inquiry

  • Home
  • About
  • Approach
  • Participate
  • News
  • Evidence
  • Support
  • Get in touch

Legal

  • Terms & Conditions
  • Cookies notice
  • Privacy Notice
  • Accessibility tool

Address

Infected Blood Inquiry
5th Floor
Aldwych House
71-91 Aldwych
London
WC2B 4HN
 
Images of individuals on the website are used with the agreement of those featured or are stock images.

Follow us

© Crown copyright. Licensed under the Open Government Licence v3.0 except where otherwise stated.